Lynx1-Loop2 Peptide Conjugates for Blood-Brain Barrier Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cognitive enhancement and alleviating cognitive decline associated with diseases like Alzheimer's and Parkinson's are ineffective due to challenges in delivering therapeutic agents across the blood-brain barrier.
Innovation Solution
The use of lynx1-loop2-derived peptides, which can cross the blood-brain barrier, conjugated with effector agents such as siRNA to deliver therapeutic agents specifically to targets inside the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used, then cognitive enhancement potential is achieved, but delivery across the blood-brain barrier fails
Solution Approach 1:
The patent uses a peptide mediator that specifically binds to nicotinic acetylcholine receptors to facilitate the transport of therapeutic agents across the blood-brain barrier. This intermediary peptide acts as a shuttle, carrying the effector agent from the bloodstream into the brain tissue without requiring direct penetration of the barrier by the therapeutic agent itself.
Solution Approach 2:
The invention creates a composite delivery system consisting of a peptide conjugated to an effector agent. This composite structure combines the blood-brain barrier penetrating capability of the peptide with the therapeutic function of the effector agent, enabling targeted delivery to brain tissue while maintaining the therapeutic properties of the original agent.
2Reliability
If rabies-derived or toxin-derived peptides are used, then blood-brain barrier crossing is achieved, but safety concerns arise
Solution Approach 1:
The patent extracts only the essential functional domain (loop 2) from the full-length rabies virus glycoprotein or toxin molecule. This extracted peptide fragment retains the ability to bind nicotinic acetylcholine receptors and cross the blood-brain barrier while eliminating the harmful components present in the full-length viral or toxic proteins.
Solution Approach 2:
The invention uses a short peptide fragment instead of a large protein molecule. This smaller peptide is less immunogenic and poses fewer safety risks while still achieving the desired blood-brain barrier penetration function. The peptide can be synthesized chemically and is more stable than full-length protein-based solutions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lynx1-loop2-derived peptide conjugates effectively transport effector agents across the blood-brain barrier, demonstrating potential for cognitive enhancement and therapeutic applications in neurological disorders.
Implementation Method 1
by binding to the nicotinic acetylcholine receptor
Data Source
AI summary
Compositions and methods are provided including a transporter peptide derived from the loop2 domain of the neuronally-derived lynx1 protein which can be conjugated to an effector agent to form a transporter-effector complex for transport of the therapeutic effector agent to a target that is found across the blood brain barrier.